ArticleCurrent microbiology2022
Isolation and Identification of a Bacillus sp. from Freshwater Sediment Displaying Potent Activity Against Bacteria and Phytopathogen Fungi.
Article in Current microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Antimicrobial Properties ofAntibiotics (Basel, Switzerland) · 2023Article
- Effects of dietary chito-oligosaccharide and β-glucan on the water quality and gut microbiota, intestinal morphology, immune response, and meat quality of Chinese soft-shell turtle (Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A bacterium strain isolated from freshwater sediment of San Pablo river of Santiago de Cuba, Cuba was identified as a Bacillus sp. by Matrix-Assisted Laser Desorption/Ionization Time Of Flight Mass Spectrometry. A 16S rRNA gene analysis showed that the isolate A3 belongs to the operational group Bacillus amyloliquefaciens, while the phylogenetic analysis of the gyrA gene sequence grouped it within B. amyloliquefaciens subsp. plantarum cluster, referred now as Bacillus velezensis. In vitro antibacterial studies demonstrated the capacity of the isolate A3 to produce bioactive metabolites against Bacillus subtilis ATCC 11,778, Bacillus cereus ATCC 6633, and Staphylococcus aureus ATCC 25,923 by cross-streak, overlay, and microdilution methods. The strain also showed a high potential against the multidrug-resistant Staphylococcus aureus ATCC 700,699, ATCC 29,213, and ATCC 6538. At pH 8 and 96 h in the medium 2 of A3 culture conditions, the produced metabolites with antibacterial potential were enhanced. Some alterations in the morphology of the phytopathogens Aspergillus niger ATCC 9642, Alternaria alternata CECT 2662, and Fusarium solani CCEBI 3094 were induced by the cell-free supernatant of B. velezensis A3. A preliminary study of the nature of the bioactive compounds produced by the strain A3 showed the presence of both lipids and peptides in the culture. Those results highlight B. velezensis A3 as a promissory bacterium capable to produce bioactive metabolites with antibacterial and antifungal properties against pathogens.
Indexed as
Identifiers
36352269What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.